BMJ  2003;326 (31 May), doi:10.1136/bmj.326.7400.0-c

Reporting of clinical trials of drugs shows bias

Results from clinical studies sponsored by the pharmaceutical industry that reach the public domain are subject to bias, according to a study by Melander and colleagues (p 1171). They investigated 42 placebo controlled studies of selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority in 1983-99 and compared the published results with the results in the full reports of the studies. A major cause of bias was the tendency to publish only the more favourable per protocol results, rather than intention to treat analyses. Other causes were extensive duplicate publication and a preference for publishing only studies showing significant effects of the drug.

Related Article

Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

Hans Melander, Jane Ahlqvist-Rastad, Gertie Meijer, and Björn Beermann
BMJ 2003 326: 1171-1173. [Abstract] [Full Text] [PDF]